Medical Condition News

RSS

Glial cells promise as new target to modulate retinal synaptic plasticity after retinal injury

Different types of retinal damage could induce plastic changes of retinal synapses, which might precede the serious damage of neuron soma.

7 May 2014

Scientists identify key molecular switches that control age-related memory impairment

Even among the healthiest individuals, memory and cognitive abilities decline with age. This aspect of normal aging can affect an individual's quality of life and capability to live independently but the rate of decline is variable across individuals.

7 May 2014

New research shows cataract surgery reduces number of falls in older patients

New research finds that cataract surgery dramatically decreases the number of falls individuals suffer due to poor vision.

7 May 2014

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

More than a million people are treated for mild traumatic brain injuries in U.S. hospitals and emergency rooms each year. Yet few receive appropriate psychological and social follow-up care that can make the difference in whether or not they fully recover.

7 May 2014

Monthly injections to counteract AMD may not be necessary, say researchers

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary.

7 May 2014

Protein molecule seems to slow progression of deadly lung disease

Researchers at the University of Illinois at Chicago College of Medicine have discovered a protein molecule that seems to slow the progression of pulmonary fibrosis, a progressive lung disease that is often fatal three to five years after diagnosis.

7 May 2014

IKKβ links vascular inflammation to obesity and atherosclerosis development

A study in The Journal of Experimental Medicine shows that IκB kinase β (IKKβ) functions in smooth muscle cells to regulate vascular inflammatory responses and atherosclerosis development.

7 May 2014

Snacking linked with abdominal fat and fatty liver

Researchers from The Netherlands found that snacking on high-fat and high-sugar foods was independently associated with abdominal fat and fatty liver (hepatic steatosis).

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.

6 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

New approach for auditory localization of patients with hearing aids under background noise

Patients with implanted artificial cochlea often complain that they cannot recognize speech well in natural environments, especially if background of noise is present.

6 May 2014

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

While many parents-to-be are aware that the health of their baby starts before they've actually arrived into the world, recent research reveals that "harm" (i.e., tobacco smoke, dirty air, poor nutrition, even preeclampsia) may not present itself disease-wise until well into adulthood or when a second harmful "hit" triggers the individual's susceptibility.

6 May 2014

Naurex's two lead antidepressant programs achieve major milestones

Naurex Inc., a privately held biopharmaceutical company leveraging its unique platform to develop novel drugs for diseases of the central nervous system (CNS), today announced that its two lead antidepressant programs achieved major milestones.

6 May 2014

CathMaps+ world's first mobile application for people with elevated risk of cardiac incident

CathMaps+ will demonstrate how mobile technology can provide emergency assistance and peace of mind to millions of Americans at risk for a cardiac event.

6 May 2014

Argon Medical Devices starts marketing CLEANERXT Rotational Thrombectomy System

Argon Medical Devices, Inc. announced today that the company has begun marketing the CLEANERXT Rotational Thrombectomy System as a new addition to the CLEANER family of dialysis products.

6 May 2014

Pregnant women who watched TV while eating are more likely to have obese children

Turning the TV off during mealtimes to help prevent childhood obesity may need to start even before a child is born, according to a study to be presented Tuesday, May 6, at the Pediatric Academic Societies (PAS) annual meeting in Vancouver, British Columbia, Canada.

6 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

Medical Condition News

Glial cells promise as new target to modulate retinal synaptic plasticity after retinal injury

Scientists identify key molecular switches that control age-related memory impairment

New research shows cataract surgery reduces number of falls in older patients

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

Monthly injections to counteract AMD may not be necessary, say researchers

Protein molecule seems to slow progression of deadly lung disease

IKKβ links vascular inflammation to obesity and atherosclerosis development

Snacking linked with abdominal fat and fatty liver

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

FDA accepts Merck's MK-3475 BLA for review

New approach for auditory localization of patients with hearing aids under background noise

Rat pups exposed to tobacco smoke are at higher risk of developing metabolic disease

Naurex's two lead antidepressant programs achieve major milestones

CathMaps+ world's first mobile application for people with elevated risk of cardiac incident

Argon Medical Devices starts marketing CLEANERXT Rotational Thrombectomy System

Pregnant women who watched TV while eating are more likely to have obese children

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

Debiopharm signs new license and research agreement with Yale University

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News